FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991619375> ?p ?o ?g. }

• W1991619375 endingPage "39.e2" @default.
• W1991619375 startingPage "34" @default.
• W1991619375 abstract "Objective To evaluate the incidence of death or neurodevelopmental impairment (NDI) at 18-22 months corrected age in subjects enrolled in a trial of early dexamethasone treatment to prevent death or chronic lung disease in extremely low birth weight infants. Study design Evaluation of infants at 18-22 months corrected age included anthropomorphic measurements, a standard neurological examination, and the Bayley Scales of Infant Development-II, including the Mental Developmental Index and the Psychomotor Developmental Index. NDI was defined as moderate or severe cerebral palsy, Mental Developmental Index or Psychomotor Developmental Index <70, blindness, or hearing impairment. Results Death or NDI at 18-22 months corrected age was similar in the dexamethasone and placebo groups (65% vs 66%, P = .99 among those with known outcome). The proportion of survivors with NDI was also similar, as were mean values for weight, length, and head circumference and the proportion of infants with poor growth (50% vs 41%, P = .42 for weight less than 10th percentile); 49% of infants in the placebo group received treatment with corticosteroid compared with 32% in the dexamethasone group (P = .02). Conclusion The risk of death or NDI and rate of poor growth were high but similar in the dexamethasone and placebo groups. The lack of a discernible effect of early dexamethasone on neurodevelopmental outcome may be due to frequent clinical corticosteroid use in the placebo group. To evaluate the incidence of death or neurodevelopmental impairment (NDI) at 18-22 months corrected age in subjects enrolled in a trial of early dexamethasone treatment to prevent death or chronic lung disease in extremely low birth weight infants. Evaluation of infants at 18-22 months corrected age included anthropomorphic measurements, a standard neurological examination, and the Bayley Scales of Infant Development-II, including the Mental Developmental Index and the Psychomotor Developmental Index. NDI was defined as moderate or severe cerebral palsy, Mental Developmental Index or Psychomotor Developmental Index <70, blindness, or hearing impairment. Death or NDI at 18-22 months corrected age was similar in the dexamethasone and placebo groups (65% vs 66%, P = .99 among those with known outcome). The proportion of survivors with NDI was also similar, as were mean values for weight, length, and head circumference and the proportion of infants with poor growth (50% vs 41%, P = .42 for weight less than 10th percentile); 49% of infants in the placebo group received treatment with corticosteroid compared with 32% in the dexamethasone group (P = .02). The risk of death or NDI and rate of poor growth were high but similar in the dexamethasone and placebo groups. The lack of a discernible effect of early dexamethasone on neurodevelopmental outcome may be due to frequent clinical corticosteroid use in the placebo group." @default.
• W1991619375 created "2016-06-24" @default.
• W1991619375 creator A5001263550 @default.
• W1991619375 creator A5002191606 @default.
• W1991619375 creator A5004762558 @default.
• W1991619375 creator A5005196817 @default.
• W1991619375 creator A5005768091 @default.
• W1991619375 creator A5006539748 @default.
• W1991619375 creator A5010773250 @default.
• W1991619375 creator A5014098212 @default.
• W1991619375 creator A5018533843 @default.
• W1991619375 creator A5020021261 @default.
• W1991619375 creator A5029079435 @default.
• W1991619375 creator A5032318856 @default.
• W1991619375 creator A5037158559 @default.
• W1991619375 creator A5040294264 @default.
• W1991619375 creator A5044405108 @default.
• W1991619375 creator A5047276769 @default.
• W1991619375 creator A5055733234 @default.
• W1991619375 creator A5056314576 @default.
• W1991619375 creator A5057878218 @default.
• W1991619375 creator A5073333755 @default.
• W1991619375 creator A5078027978 @default.
• W1991619375 creator A5080368882 @default.
• W1991619375 creator A5080892509 @default.
• W1991619375 creator A5084108007 @default.
• W1991619375 date "2014-01-01" @default.
• W1991619375 modified "2023-10-02" @default.
• W1991619375 title "Death or Neurodevelopmental Impairment at 18 to 22 Months Corrected Age in a Randomized Trial of Early Dexamethasone to Prevent Death or Chronic Lung Disease in Extremely Low Birth Weight Infants" @default.
• W1991619375 cites W1913147314 @default.
• W1991619375 cites W1984794557 @default.
• W1991619375 cites W2002642430 @default.
• W1991619375 cites W2008081165 @default.
• W1991619375 cites W2014273178 @default.
• W1991619375 cites W2016465069 @default.
• W1991619375 cites W202225520 @default.
• W1991619375 cites W2052191146 @default.
• W1991619375 cites W2052971975 @default.
• W1991619375 cites W2067175105 @default.
• W1991619375 cites W2067332782 @default.
• W1991619375 cites W2068515283 @default.
• W1991619375 cites W2073218746 @default.
• W1991619375 cites W2073863557 @default.
• W1991619375 cites W2109256570 @default.
• W1991619375 cites W2116618515 @default.
• W1991619375 cites W2122848273 @default.
• W1991619375 cites W2127168252 @default.
• W1991619375 cites W2133527597 @default.
• W1991619375 cites W2134586161 @default.
• W1991619375 cites W2141078013 @default.
• W1991619375 cites W2156168620 @default.
• W1991619375 cites W2170895352 @default.
• W1991619375 cites W2317266832 @default.
• W1991619375 cites W4237379122 @default.
• W1991619375 cites W4252831818 @default.
• W1991619375 cites W4378195497 @default.
• W1991619375 doi "https://doi.org/10.1016/j.jpeds.2013.07.027" @default.
• W1991619375 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4120744" @default.
• W1991619375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23992673" @default.
• W1991619375 hasPublicationYear "2014" @default.
• W1991619375 type Work @default.
• W1991619375 sameAs 1991619375 @default.
• W1991619375 citedByCount "27" @default.
• W1991619375 countsByYear W19916193752014 @default.
• W1991619375 countsByYear W19916193752015 @default.
• W1991619375 countsByYear W19916193752016 @default.
• W1991619375 countsByYear W19916193752017 @default.
• W1991619375 countsByYear W19916193752019 @default.
• W1991619375 countsByYear W19916193752020 @default.
• W1991619375 countsByYear W19916193752021 @default.
• W1991619375 countsByYear W19916193752022 @default.
• W1991619375 countsByYear W19916193752023 @default.
• W1991619375 crossrefType "journal-article" @default.
• W1991619375 hasAuthorship W1991619375A5001263550 @default.
• W1991619375 hasAuthorship W1991619375A5002191606 @default.
• W1991619375 hasAuthorship W1991619375A5004762558 @default.
• W1991619375 hasAuthorship W1991619375A5005196817 @default.
• W1991619375 hasAuthorship W1991619375A5005768091 @default.
• W1991619375 hasAuthorship W1991619375A5006539748 @default.
• W1991619375 hasAuthorship W1991619375A5010773250 @default.
• W1991619375 hasAuthorship W1991619375A5014098212 @default.
• W1991619375 hasAuthorship W1991619375A5018533843 @default.
• W1991619375 hasAuthorship W1991619375A5020021261 @default.
• W1991619375 hasAuthorship W1991619375A5029079435 @default.
• W1991619375 hasAuthorship W1991619375A5032318856 @default.
• W1991619375 hasAuthorship W1991619375A5037158559 @default.
• W1991619375 hasAuthorship W1991619375A5040294264 @default.
• W1991619375 hasAuthorship W1991619375A5044405108 @default.
• W1991619375 hasAuthorship W1991619375A5047276769 @default.
• W1991619375 hasAuthorship W1991619375A5055733234 @default.
• W1991619375 hasAuthorship W1991619375A5056314576 @default.
• W1991619375 hasAuthorship W1991619375A5057878218 @default.
• W1991619375 hasAuthorship W1991619375A5073333755 @default.
• W1991619375 hasAuthorship W1991619375A5078027978 @default.
• W1991619375 hasAuthorship W1991619375A5080368882 @default.
• W1991619375 hasAuthorship W1991619375A5080892509 @default.
• W1991619375 hasAuthorship W1991619375A5084108007 @default.
• W1991619375 hasBestOaLocation W19916193752 @default.

• next